Fig. 5From: Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectivesinTandem 1 and inTandem 2 clinical trials: study design (a) and percentage of patients that achieve composite endpoints (Hba1c < 7%, no weight gain, no severe hypoglycemic event or diabetic ketoacidosis) at week 52 (b). P# = sota 200 mg vs placebo; P* = sota 400 mg vs placeboBack to article page